53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients
Publication
, Conference
Mahtani, R; Lyman, GH; Rifkin, R; Dale, D; Brookhart, A; Lewis, S; Decosta, L; Lawrence, T; Belani, R; Crawford, J
Published in: Annals of Oncology
May 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
May 2021
Volume
32
Start / End Page
S43 / S43
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Mahtani, R., Lyman, G. H., Rifkin, R., Dale, D., Brookhart, A., Lewis, S., … Crawford, J. (2021). 53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients. In Annals of Oncology (Vol. 32, pp. S43–S43). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.03.067
Mahtani, R., G. H. Lyman, R. Rifkin, D. Dale, A. Brookhart, S. Lewis, L. Decosta, T. Lawrence, R. Belani, and J. Crawford. “53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients.” In Annals of Oncology, 32:S43–S43. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.03.067.
Mahtani R, Lyman GH, Rifkin R, Dale D, Brookhart A, Lewis S, et al. 53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients. In: Annals of Oncology. Elsevier BV; 2021. p. S43–S43.
Mahtani, R., et al. “53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S43–S43. Crossref, doi:10.1016/j.annonc.2021.03.067.
Mahtani R, Lyman GH, Rifkin R, Dale D, Brookhart A, Lewis S, Decosta L, Lawrence T, Belani R, Crawford J. 53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients. Annals of Oncology. Elsevier BV; 2021. p. S43–S43.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
May 2021
Volume
32
Start / End Page
S43 / S43
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis